Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer
"We are advancing a diverse, late-stage pipeline with five Breakthrough Therapy Designations across multiple indications, all with high unmet medical need," said
"This is an exciting time as
About
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
Zokinvy® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our plans and objectives, are forward-looking statements. These forward-looking statements include terminology such as "seek," "advance," "believe," "will," "may," "continue," or the negative of these terms. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including those described in the "Risk Factors" sections in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Investors and Media:
Chief Financial Officer
Email: [email protected]
Phone: 1-650-272-6138 ext. 1007
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-appoints-erik-atkisson-as-general-counsel-and-chief-compliance-officer-301381268.html
SOURCE